Tags : Clinical Collaboration

MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for

Shots: MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of dual regimen for multiple cancer indications in a P-I study The collaboration will further explore the therapeutic potential of combination therapy, TJC4 with Keytruda across […]Read More

Bioxcel, Nektar and Merck KGaA in a Triple Collaboration for

Shots: The companies entered into a clinical collaboration for evaluating BioXcel’s BXCL701, Nektar’s NKTR-214 & Avelumab (co-developed and co-commercialized by Merck KGaA and Pfizer) as a triple combination therapy for pancreatic cancer In Nov,2017, BTI and Nektar Therapeutics initially collaborated for preclinical development and expand their collaboration on 24 Sept,2018 for novel triple combination therapy […]Read More

AstraZeneca and AVEO Oncology Enter into an Immuno-Oncology Clinical Collaboration

Shots: AstraZeneca and AVEO collaborates to evaluate safety and efficacy of AstraZeneca’s Imfinzi (durvalumab) + AVEO’s Fotivda (tivozanib) in P-I/II for 1L HCC or liver cancer AVEO plans to initiate the onset of P-I trial for the combination therapy in 2019, with equal cost sharing Imfinzi (durvalumab) is mAb binds with PD-L1, further blocking its interaction with PD-1 and […]Read More